Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Healthy Male Subjects

NCT03056326 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.

NCT NCT03056326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03056326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Healthy Male Subjects
Lead sponsor
Chiesi Farmaceutici S.p.A.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
July 31, 2017
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, non-cystic fibrosis bronchiectasis